Clinical Citations & References

⚕️ Medical Disclaimer

PainIQ provides general educational information about gabapentin and Lyrica (pregabalin) medications only. This content does not constitute medical advice, diagnosis, or treatment. All educational content is based on peer-reviewed clinical literature and established FDA prescribing guidelines. Always consult your physician before making any changes to your medication regimen. Never alter or discontinue medications without physician supervision. In a medical emergency call 911.

Gabapentin — Clinical Evidence Base

Efficacy — Neuropathic Pain

Reference 1

Gabapentin for chronic neuropathic pain and fibromyalgia in adults

Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS.

Cochrane Database of Systematic Reviews. 2014;(4):CD007938.

View on PubMed →

Dosing — Absorption Pharmacokinetics

Reference 2

Gabapentin bioavailability: dose proportionality and the effect of food

Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN.

Epilepsy Research. 2000;40(2-3):123-127.

View on PubMed →

Post-Herpetic Neuralgia

Reference 3

Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial

Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L.

JAMA. 1998;280(21):1837-1842.

View on PubMed →

Diabetic Neuropathy

Reference 4

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus

Backonja M, Beydoun A, Edwards KR, et al.

JAMA. 1998;280(21):1831-1836.

View on PubMed →

Withdrawal — Discontinuation Safety

Reference 5

Gabapentin withdrawal syndrome in the presence of a taper

Norton JW.

Bipolar Disorders. 2001;3(4):192-194.

View on PubMed →

Safety — Opioid Interaction

Reference 6

Gabapentinoid use and risk of opioid-related death: population-based case-crossover study

Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W.

BMJ. 2017;356:j827.

View on PubMed →

Lyrica (Pregabalin) — Clinical Evidence Base

Fibromyalgia — FDA Approval Basis

Reference 7

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

Crofford LJ, Rowbotham MC, Mease PJ, et al.

Arthritis and Rheumatism. 2005;52(4):1264-1273.

View on PubMed →

Diabetic Peripheral Neuropathy

Reference 8

Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial

Lesser H, Sharma U, LaMoreaux L, Poole RM.

Neurology. 2004;63(11):2104-2110.

View on PubMed →

Weight Gain — Side Effects

Reference 9

Weight gain associated with pregabalin treatment for neuropathic pain

Tassone DM, Boyce E, Guyer J, Nuzum D.

Pharmacotherapy. 2007;27(7):1002-1007.

View on PubMed →

Clinical Guidelines

AAN Guidelines

Reference 10

Evidence-based guideline: Treatment of painful diabetic neuropathy

Bril V, England J, Franklin GM, et al. American Academy of Neurology.

Neurology. 2011;76(20):1758-1765.

View on PubMed →

Neuropathic Pain Guidelines

Reference 11

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

Finnerup NB, Attal N, Haroutounian S, et al.

The Lancet Neurology. 2015;14(2):162-173.

View on PubMed →

FDA Prescribing Information

Reference 12

Gabapentin (Neurontin) — FDA Prescribing Information and Drug Label

U.S. Food and Drug Administration.

FDA Drug Database. Current labeling.

View FDA Label →

FDA Prescribing Information

Reference 13

Pregabalin (Lyrica) — FDA Prescribing Information and Drug Label

U.S. Food and Drug Administration.

FDA Drug Database. Current labeling.

View FDA Label →